|
1
|
Barton GM and Medzhitov R: Toll-like
receptors and their ligands. Curr Top Microbiol Immunol. 270:81–92.
2002.PubMed/NCBI
|
|
2
|
Iwasaki A and Medzhitov R: Toll-like
receptor control of the adaptive immune responses. Nat Immunol.
5:987–995. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gibson SJ, Lindh JM, Riter TR, Gleason RM,
Rogers LM, Fuller AE, Oesterich JL, Gorden KB, Qiu X, McKane SW, et
al: Plasmacytoid dendritic cells produce cytokines and mature in
response to the TLR7 agonists, imiquimod and resiquimod. Cell
Immunol. 218:74–86. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
van Duin D, Medzhitov R and Shaw AC:
Triggering TLR signaling in vaccination. Trends Immunol. 27:49–55.
2006. View Article : Google Scholar
|
|
5
|
Paulos CM, Kaiser A, Wrzesinski C,
Hinrichs CS, Cassard L, Boni A, Muranski P, Sanchez-Perez L, Palmer
DC, Yu Z, et al: Toll-like receptors in tumor immunotherapy. Clin
Cancer Res. 13:5280–5289. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Adams S: Toll-like receptor agonists in
cancer therapy. Immunotherapy. 1:949–964. 2009. View Article : Google Scholar
|
|
7
|
Lakshminarayanan V, Thompson P, Wolfert
MA, Buskas T, Bradley JM, Pathangey LB, Madsen CS, Cohen PA,
Gendler SJ and Boons GJ: Immune recognition of tumor-associated
mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated
MUC1 tripartite vaccine. Proc Natl Acad Sci USA. 109:261–266. 2012.
View Article : Google Scholar :
|
|
8
|
Hurwitz AA and Watkins SK: Immune
suppression in the tumor microenvironment: A role for dendritic
cell-mediated tolerization of T cells. Cancer Immunol Immunother.
61:289–293. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cheng C, Qu QX, Shen Y, Lv YT, Zhu YB,
Zhang XG and Huang JA: Overexpression of B7-H4 in tumor infiltrated
dendritic cells. J Immunoassay Immunochem. 32:353–364. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jochems C and Schlom J: Tumor-infiltrating
immune cells and prognosis: The potential link between conventional
cancer therapy and immunity. Exp Biol Med (Maywood). 236:567–579.
2011. View Article : Google Scholar
|
|
11
|
Aranda F, Vacchelli E, Obrist F, Eggermont
A, Galon J, Sautès-Fridman C, Cremer I, Henrik Ter, Meulen J,
Zitvogel L, Kroemer G, et al: Trial Watch: Toll-like receptor
agonists in oncological indications. OncoImmunology. 3:e291792014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hemmi H, Kaisho T, Takeuchi O, Sato S,
Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K and Akira S:
Small anti-viral compounds activate immune cells via the TLR7
MyD88-dependent signaling pathway. Nat Immunol. 3:196–200. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lee J, Chuang TH, Redecke V, She L, Pitha
PM, Carson DA, Raz E and Cottam HB: Molecular basis for the
immunostimulatory activity of guanine nucleoside analogs:
Activation of Toll-like receptor 7. Proc Natl Acad Sci USA.
100:6646–6651. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Stary G, Bangert C, Tauber M, Strohal R,
Kopp T and Stingl G: Tumoricidal activity of TLR7/8-activated
inflammatory dendritic cells. J Exp Med. 204:1441–1451. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhu J, He S, Du J, Wang Z, Li W, Chen X,
Jiang W, Zheng D and Jin G: Local administration of a novel
Toll-like receptor 7 agonist in combination with doxorubicin
induces durable tumouricidal effects in a murine model of T cell
lymphoma. J Hematol Oncol. 8:212015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zamarin D, Holmgaard RB, Subudhi SK, Park
JS, Mansour M, Palese P, Merghoub T, Wolchok JD and Allison JP:
Localized oncolytic virotherapy overcomes systemic tumor resistance
to immune checkpoint blockade immunotherapy. Sci Transl Med.
6:226ra322014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Stewart TJ and Smyth MJ: Improving cancer
immunotherapy by targeting tumor-induced immune suppression. Cancer
Metastasis Rev. 30:125–140. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kanzler H, Barrat FJ, Hessel EM and
Coffman RL: Therapeutic targeting of innate immunity with Toll-like
receptor agonists and antagonists. Nat Med. 13:552–559. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Stojanovic A and Cerwenka A: Natural
killer cells and solid tumors. J Innate Immun. 3:355–364. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Whiteside TL: Immune suppression in
cancer: Effects on immune cells, mechanisms and future therapeutic
intervention. Semin Cancer Biol. 16:3–15. 2006. View Article : Google Scholar
|
|
21
|
Marcus A, Gowen BG, Thompson TW, Iannello
A, Ardolino M, Deng W, Wang L, Shifrin N and Raulet DH: Recognition
of tumors by the innate immune system and natural killer cells. Adv
Immunol. 122:91–128. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cho D1, Shook DR, Shimasaki N, Chang YH,
Fujisaki H and Campana D: Cytotoxicity of activated natural killer
cells against pediatric solid tumors. Clin Cancer Res.
16:3901–3909. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Moreno M, Mol BM, von Mensdorff-Pouilly S,
Verheijen RH, von Blomberg BM, van den Eertwegh AJ, Scheper RJ and
Bontkes HJ: Toll-like receptor agonists and invariant natural
killer T-cells enhance antibody-dependent cell-mediated
cytotoxicity (ADCC). Cancer Lett. 272:70–76. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lauzon NM, Mian F, MacKenzie R and Ashkar
AA: The direct effects of Toll-like receptor ligands on human NK
cell cytokine production and cytotoxicity. Cell Immunol.
241:102–112. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vivier E, Raulet DH, Moretta A, Caligiuri
MA, Zitvogel L, Lanier LL, Yokoyama WM and Ugolini S: Innate or
adaptive immunity? The example of natural killer cells. Science.
331:44–49. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chanmee T, Ontong P, Konno K and Itano N:
Tumor-associated macrophages as major players in the tumor
microenvironment. Cancers (Basel). 6:1670–1690. 2014. View Article : Google Scholar
|
|
27
|
Mosser DM and Edwards JP: Exploring the
full spectrum of macrophage activation. Nat Rev Immunol. 8:958–969.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ostuni R, Kratochvill F, Murray PJ and
Natoli G: Macrophages and cancer: From mechanisms to therapeutic
implications. Trends Immunol. 36:229–239. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lopez-Castejón G, Baroja-Mazo A and
Pelegrín P: Novel macrophage polarization model: From gene
expression to identification of new anti-inflammatory molecules.
Cell Mol Life Sci. 68:3095–3107. 2011. View Article : Google Scholar
|
|
30
|
Ullrich E, Ménard C, Flament C, Terme M,
Mignot G, Bonmort M, Plumas J, Chaperot L, Chaput N and Zitvogel L:
Dendritic cells and innate defense against tumor cells. Cytokine
Growth Factor Rev. 19:79–92. 2008. View Article : Google Scholar
|
|
31
|
Singh M, Khong H, Dai Z, Huang XF, Wargo
JA, Cooper ZA, Vasilakos JP, Hwu P and Overwijk WW: Effective
innate and adaptive antimelanoma immunity through localized TLR7/8
activation. J Immunol. 193:4722–4731. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mao Y, Keller ET, Garfield DH, Shen K and
Wang J: Stromal cells in tumor microenvironment and breast cancer.
Cancer Metastasis Rev. 32:303–315. 2013. View Article : Google Scholar
|
|
33
|
Diederichsen AC, Hjelmborg J, Christensen
PB, Zeuthen J and Fenger C: Prognostic value of the
CD4+/CD8+ ratio of tumour infiltrating
lymphocytes in colorectal cancer and HLA-DR expression on tumour
cells. Cancer Immunol Immunother. 52:423–428. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Broomfield SA, van der Most RG, Prosser
AC, Mahendran S, Tovey MG, Smyth MJ, Robinson BW and Currie AJ:
Locally administered TLR7 agonists drive systemic antitumor immune
responses that are enhanced by anti-CD40 immunotherapy. J Immunol.
182:5217–5224. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hiraoka K, Miyamoto M, Cho Y, Suzuoki M,
Oshikiri T, Nakakubo Y, Itoh T, Ohbuchi T, Kondo S and Katoh H:
Concurrent infiltration by CD8+ T cells and
CD4+ T cells is a favourable prognostic factor in
non-small-cell lung carcinoma. Br J Cancer. 94:275–280. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Reissfelder C, Stamova S, Gossmann C,
Braun M, Bonertz A, Walliczek U, Grimm M, Rahbari NN, Koch M,
Saadati M, et al: Tumor-specific cytotoxic T lymphocyte activity
determines colorectal cancer patient prognosis. J Clin Invest.
125:739–751. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yamaguchi T and Sakaguchi S: Regulatory T
cells in immune surveillance and treatment of cancer. Semin Cancer
Biol. 16:115–123. 2006. View Article : Google Scholar
|
|
38
|
Wang C, Zhou Q, Wang X, Wu X, Chen X, Li
J, Zhu Z, Liu B and Su L: The TLR7 agonist induces tumor regression
both by promoting CD4+ T cells proliferation and by
reversing T regulatory cell-mediated suppression via dendritic
cells. Oncotarget. 6:1779–1789. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Nelson D, Fisher S and Robinson B: The
'Trojan Horse' approach to tumor immunotherapy: Targeting the tumor
microenvironment. J Immunol Res. 2014:7890692014. View Article : Google Scholar
|
|
40
|
Van der Jeught K, Bialkowski L,
Daszkiewicz L, Broos K, Goyvaerts C, Renmans D, Van Lint S, Heirman
C, Thielemans K and Breckpot K: Targeting the tumor
microenvironment to enhance antitumor immune responses. Oncotarget.
6:1359–1381. 2015. View Article : Google Scholar : PubMed/NCBI
|
